Wouldnât it be nice to grow your ASX share portfolio from $20,000 to $1 million?
Well, the good news is that this is entirely possible. All you need is time, patience, a portfolio of high-quality ASX 200 shares, and compounding.
How to turn $20k into $1 million with ASX 200 shares
Historically, the stock market has provided investors with an average annual return of approximately 10% per annum.
And while there is no guarantee that it will continue to generate returns of this nature in the future, if it were to do so, your single $20,000 investment would grow into $1 million after 41 years.
Maybe thatâs too long for you? If it is, donât worry. All you need to do is add to your portfolio each year and youâll cut down the time it takes to reach your million-dollar target.
For example, if you were able to invest $20,000 each year, your portfolio would grow to our target value after 17 years.
Alternatively, starting with a $20,000 investment and then investing $10,000 into high-quality ASX 200 shares each year would get you to $1 million in 22 years if you averaged 10% per annum.
Which shares should you buy?
I would aim to buy quality over quantity and focus on building a portfolio filled with ASX 200 shares that have the following characteristics:
- Competitive advantages
- Fair valuations
- Strong long-term growth prospects
- Sizeable addressable markets
- Growing dividends
A few ASX shares that spring to mind immediately are gaming technology company Aristocrat Leisure Limited (ASX: ALL), hearing solutions specialist Cochlear Limited (ASX: COH), and sleep treatment company ResMed Inc (ASX: RMD).
Over the last decade, these ASX shares have generated average annual total returns of 26.7%, 13.4%, and 22.4%, respectively. And based on their qualities, I would not be surprised to see them beat the market over the next decade.
The post How Iâd invest $20,000 in ASX 200 shares to aim for a million appeared first on The Motley Fool Australia.
FREE Guide for New Investors
Despite what some people may say – we believe investing in shares doesn’t have to be overwhelming or complicated…
For over a decade, we’ve been helping everyday Aussies get started on their journey.
And to help even more people cut through some of the confusion “experts’” seem to want to perpetuate – we’ve created a brand-new “how to” guide.
Yes, Claim my FREE copy!
*Returns as of March 1 2023
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- Buy these 3 ASX growth shares this month: experts
- 3 incredible ASX 200 growth shares to buy: analysts
- $20k invested in these ASX shares 10 years ago is now worth over $100k
- Guess which ASX 200 share is giving another $500 million back to its shareholders
- Buy these ASX 200 growth shares: Goldman Sachs
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/bsq64ku
Stock Pick 